Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 2/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 5/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188438 | 0.88 | AKT1 (0.38) | AKT1AKT2AKT3KCNH2FAAH | |
| SCHEMBL12391471 | 0.85 | AKT1 (0.39) | AKT1AKT2AKT3KCNH2FAAH | |
| SCHEMBL16264770 | 0.85 | AKT1 (0.39) | AKT1AKT2AKT3 | |
| SCHEMBL12188596 | 0.85 | AKT1 (0.39) | AKT1AKT2AKT3 | |
| SCHEMBL12188418 | 0.83 | AKT1 (0.53) | AKT1AKT2AKT3 | |
| SCHEMBL16151929 | 0.81 | L3MBTL1 (0.45) | KCNH2FAAHBCHE | |
| SCHEMBL12188413 | 0.81 | NPC1 (0.41) | AKT1AKT2AKT3BCHE | |
| SCHEMBL684922 | 0.80 | EPHX2 (0.46) | AKT1AKT2AKT3 | |
| SCHEMBL684125 | 0.79 | ADRB2 (0.41) | AKT1AKT2AKT3 | |
| SCHEMBL16151948 | 0.79 | HPGD (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.